secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001708599-25-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics Q1 net loss $4.8M; cash runway through Q3 2025
------------------------------------------------------------------

- Net loss attributable to Serina of $4.8M ($0.49/share) vs $15.0M ($5.38/share) in Q1 2024.
- Cash and cash equivalents $4.3M at March 31, 2025; plus $5M April private placement extends runway through Q3 2025.
- On track to dose first patient in Phase 1b trial of SER-252 for advanced Parkinson's in Q4 2025.
- Secured $15M in equity financing since late 2024, including $10M from JuvVentures and $5M private placement.
- Appointed Karen J. Wilson and Dr. Jay Venkatesan to the Board; POZ-lipid data showed no antibody response in rats.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000055/0001708599-25-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000055/ser-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer